Pharmaceuticals & Therapeutics

A new partnership gives Texas small business employees free access to a clinically proven virtual program aimed at reversing Type 2 diabetes, not just managing it.

Enveric Biosciences raises $1.5M to advance its novel psychiatric drugs. Is this small cash infusion enough to propel its promising pipeline forward?

A landmark FDA decision allows Life Biosciences to test its epigenetic reprogramming therapy, ER-100, offering new hope for restoring sight in the blind.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

With new funding, Stellular Bio is advancing an 'off-the-shelf' biologic therapy, offering new hope for Sjogren's patients and beyond.

Specialty chemical giant Lubrizol announces a multi-million-dollar investment to upgrade its Ohio HQ, boosting the local economy and its global reach.

A new partnership will test a novel drug in at-risk individuals, hoping to prevent Parkinson's disease before a diagnosis is ever made.

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.

A pivotal FDA meeting moves a novel drug forward for Dementia with Lewy Bodies, a disease with no approved therapies, offering new hope to patients.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

LuskinOIC honors a pioneer of artificial joints with a new award, celebrating a legacy of innovation and propelling the next wave of orthopaedic discovery.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

As US organ donor registrations fall, Southern Legacy of Life achieves its second-best year, saving hundreds through strategic community engagement.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

Leios Therapeutics partners with BNC Korea, securing a key investment and pathway to Asia's lucrative body contouring market for its 10XB-101 injectable.

A new external bioengineered liver has passed a crucial safety trial, offering a potential lifeline for patients with acute liver failure.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.